{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:22:58Z","timestamp":1707524578733},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,22]]},"DOI":"10.7759\/cureus.22494","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T15:36:57Z","timestamp":1645544217000},"source":"Crossref","is-referenced-by-count":0,"title":["Implementation of High-Dose-Rate, CT-Based Prostate Brachytherapy in an Academic Teaching Hospital and Residency Training Program"],"prefix":"10.7759","author":[{"given":"Daniel","family":"Brunnhoelzl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Hanania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Jaramillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linfeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavan","family":"Jhaveri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-019-03275-z","article-title":"The declining art of brachytherapy","volume":"574","author":"Eisenstein M","year":"2019","unstructured":"Eisenstein M. The declining art of brachytherapy. Nature. 2019, 574:S81. 10.1038\/d41586-019-03275-z","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.7_suppl.3","article-title":"ASCENDE-RT*: a multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer","volume":"33","author":"Morris WJ","year":"2015","unstructured":"Morris WJ, Tyldesley S, Pai HH, et al.. ASCENDE-RT*: a multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer. J Clin Oncol. 2015, 33:3. 10.1200\/jco.2015.33.7_suppl.3","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.11.026","article-title":"Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a\u00a0low-dose-rate brachytherapy boost to a\u00a0dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Morris WJ","year":"2017","unstructured":"Morris WJ, Tyldesley S, Rodda S, et al.. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a\u00a0low-dose-rate brachytherapy boost to a\u00a0dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017, 98:275-85. 10.1016\/j.ijrobp.2016.11.026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2015.02.200","article-title":"Low-dose-rate brachytherapy is superior to dose-escalated EBRT for unfavourable risk prostate cancer: the results of the ASCENDE-RT* randomized control trial","volume":"14","author":"Morris WJ","year":"2015","unstructured":"Morris WJ, Tyldesley S, Pai H, et al.. Low-dose-rate brachytherapy is superior to dose-escalated EBRT for unfavourable risk prostate cancer: the results of the ASCENDE-RT* randomized control trial. Brachytherapy. 2015, 14:12. 10.1016\/j.brachy.2015.02.200","journal-title":"Brachytherapy"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.07.2194","article-title":"An updated analysis of survival endpoints for ASCENDE-RT, a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"108","author":"Oh J","year":"2020","unstructured":"Oh J, Tyldesley S, Pai HH, et al.. An updated analysis of survival endpoints for ASCENDE-RT, a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol. 2020, 108:S62. 10.1016\/j.ijrobp.2020.07.2194","journal-title":"Int J Radiat Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.0466","article-title":"Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology\/Cancer Care Ontario joint guideline update","volume":"35","author":"Chin J","year":"2017","unstructured":"Chin J, Rumble RB, Kollmeier M, et al.. Brachytherapy for patients with prostate cancer: American Society of Clinical Oncology\/Cancer Care Ontario joint guideline update. J Clin Oncol. 2017, 35:1737-43. 10.1200\/JCO.2016.72.0466","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.10.023","article-title":"Brachytherapy training survey of radiation oncology residents","volume":"103","author":"Marcrom SR","year":"2019","unstructured":"Marcrom SR, Kahn JM, Colbert LE, et al.. Brachytherapy training survey of radiation oncology residents. Int J Radiat Oncol Biol Phys. 2019, 103:557-60. 10.1016\/j.ijrobp.2018.10.023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2016.12.015","article-title":"Brachytherapy boost for prostate cancer: trends in care and survival outcomes","volume":"16","author":"Glaser SM","year":"2017","unstructured":"Glaser SM, Dohopolski MJ, Balasubramani GK, Benoit RM, Smith RP, Beriwal S. Brachytherapy boost for prostate cancer: trends in care and survival outcomes. Brachytherapy. 2017, 16:330-41. 10.1016\/j.brachy.2016.12.015","journal-title":"Brachytherapy"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2013.08.005","article-title":"Declining use of brachytherapy for the treatment of prostate cancer","volume":"13","author":"Mahmood U","year":"2014","unstructured":"Mahmood U, Pugh T, Frank S, et al.. Declining use of brachytherapy for the treatment of prostate cancer. Brachytherapy. 2014, 13:157-62. 10.1016\/j.brachy.2013.08.005","journal-title":"Brachytherapy"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.08.022","article-title":"Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?","volume":"100","author":"Morton G","year":"2011","unstructured":"Morton G, Loblaw A, Cheung P, et al.. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?. Radiother Oncol. 2011, 100:463-7. 10.1016\/j.radonc.2011.08.022","journal-title":"Radiother Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2017.12.08","article-title":"High dose-rate brachytherapy in the treatment of prostate cancer","volume":"7","author":"Mendez LC","year":"2018","unstructured":"Mendez LC, Morton GC. High dose-rate brachytherapy in the treatment of prostate cancer. Transl Androl Urol. 2018, 7:357-70. 10.21037\/tau.2017.12.08","journal-title":"Transl Androl Urol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.06.493","article-title":"Long-term results of NRG Oncology\/RTOG 0321 a phase II trial of combined high dose rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate","volume":"18","author":"Hsu I-CJ","year":"2019","unstructured":"Hsu I-CJ, Rodgers J, Shinohara K, et al.. Long-term results of NRG Oncology\/RTOG 0321 a phase II trial of combined high dose rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate. Brachytherapy. 2019, 18:37-8. 10.1016\/j.ijrobp.2019.06.493","journal-title":"Brachytherapy"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2012.01.007","article-title":"Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer","volume":"103","author":"Hoskin PJ","year":"2012","unstructured":"Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012, 103:217-22. 10.1016\/j.radonc.2012.01.007","journal-title":"Radiother Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.0587","article-title":"Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9-10 prostate cancer","volume":"319","author":"Kishan AU","year":"2018","unstructured":"Kishan AU, Cook RR, Ciezki JP, et al.. Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9-10 prostate cancer. JAMA. 2018, 319:896-905. 10.1001\/jama.2018.0587","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2018.08.008","article-title":"Using a surgical prostate-specific antigen threshold of >0.2\u00a0ng\/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial","volume":"17","author":"Morris WJ","year":"2018","unstructured":"Morris WJ, Pickles T, Keyes M. Using a surgical prostate-specific antigen threshold of >0.2\u00a0ng\/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial. Brachytherapy. 2018, 17:837-44. 10.1016\/j.brachy.2018.08.008","journal-title":"Brachytherapy"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2017.76","article-title":"The evolution of brachytherapy for prostate cancer","volume":"14","author":"Zaorsky NG","year":"2017","unstructured":"Zaorsky NG, Davis BJ, Nguyen PL, et al.. The evolution of brachytherapy for prostate cancer. Nat Rev Urol. 2017, 14:415-39. 10.1038\/nrurol.2017.76","journal-title":"Nat Rev Urol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.08.048","article-title":"Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321","volume":"78","author":"Hsu IC","year":"2010","unstructured":"Hsu IC, Bae K, Shinohara K, et al.. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys. 2010, 78:751-8. 10.1016\/j.ijrobp.2009.08.048","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.07.2290","article-title":"High-dose-rate monotherapy for localized prostate cancer: 10-year results","volume":"94","author":"Hauswald H","year":"2016","unstructured":"Hauswald H, Kamrava MR, Fallon JM, et al.. High-dose-rate monotherapy for localized prostate cancer: 10-year results. Int J Radiat Oncol Biol Phys. 2016, 94:667-74. 10.1016\/j.ijrobp.2015.07.2290","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2017.06.014","article-title":"Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer","volume":"124","author":"Hoskin P","year":"2017","unstructured":"Hoskin P, Rojas A, Ostler P, Hughes R, Alonzi R, Lowe G. Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer. Radiother Oncol. 2017, 124:56-60. 10.1016\/j.radonc.2017.06.014","journal-title":"Radiother Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.02.009","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19\u00a0Gy or two fractions of 13.5\u00a0Gy","volume":"146","author":"Morton G","year":"2020","unstructured":"Morton G, McGuffin M, Chung HT, et al.. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19\u00a0Gy or two fractions of 13.5\u00a0Gy. Radiother Oncol. 2020, 146:90-6. 10.1016\/j.radonc.2020.02.009","journal-title":"Radiother Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.02.010","article-title":"Five-year outcomes of a single-institution prospective trial of 19-Gy single-fraction high-dose-rate brachytherapy for low- and intermediate-risk prostate cancer","volume":"104","author":"Siddiqui ZA","year":"2019","unstructured":"Siddiqui ZA, Gustafson GS, Ye H, et al.. Five-year outcomes of a single-institution prospective trial of 19-Gy single-fraction high-dose-rate brachytherapy for low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2019, 104:1038-44. 10.1016\/j.ijrobp.2019.02.010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.09.007","article-title":"Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: outcomes from two clinical trials with and without an MRI-guided boost","volume":"154","author":"Alayed Y","year":"2021","unstructured":"Alayed Y, Loblaw A, McGuffin M, et al.. Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: outcomes from two clinical trials with and without an MRI-guided boost. Radiother Oncol. 2021, 154:29-35. 10.1016\/j.radonc.2020.09.007","journal-title":"Radiother Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2019.08.003","article-title":"HDR prostate brachytherapy","volume":"30","author":"Crook J","year":"2020","unstructured":"Crook J, Marb\u00e1n M, Batchelar D. HDR prostate brachytherapy. Semin Radiat Oncol. 2020, 30:49-60. 10.1016\/j.semradonc.2019.08.003","journal-title":"Semin Radiat Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00097-2","article-title":"High dose-rate afterloading 192Iridium prostate brachytherapy: Feasibility report","volume":"41","author":"Mate TP","year":"1998","unstructured":"Mate TP, Gottesman JE, Hatton J, Gribble M, Van Hollebeke L. High dose-rate afterloading 192Iridium prostate brachytherapy: Feasibility report. Int J Radiat Oncol Biol Phys. 1998, 41:525-33. 10.1016\/S0360-3016(98)00097-2","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.05.044","article-title":"High-dose-rate brachytherapy as monotherapy for intermediate- and high-risk prostate cancer: clinical results for a median 8-year follow-up","volume":"94","author":"Yoshioka Y","year":"2016","unstructured":"Yoshioka Y, Suzuki O, Isohashi F, et al.. High-dose-rate brachytherapy as monotherapy for intermediate- and high-risk prostate cancer: clinical results for a median 8-year follow-up. Int J Radiat Oncol Biol Phys. 2016, 94:675-82. 10.1016\/j.ijrobp.2015.05.044","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.10.035","article-title":"Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy","volume":"79","author":"Martinez AA","year":"2011","unstructured":"Martinez AA, Gonzalez J, Ye H, et al.. Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2011, 79:363-70. 10.1016\/j.ijrobp.2009.10.035","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2020.02.002","article-title":"Building a high-dose-rate prostate brachytherapy program with real-time ultrasound-based planning: initial safety, quality, and outcome results","volume":"5","author":"Zhang H","year":"2020","unstructured":"Zhang H, Kang S, Ali N, et al.. Building a high-dose-rate prostate brachytherapy program with real-time ultrasound-based planning: initial safety, quality, and outcome results. Adv Radiat Oncol. 2020, 5:388-95. 10.1016\/j.adro.2020.02.002","journal-title":"Adv Radiat Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-012-0987-x","article-title":"Pudendal nerve block in HDR-brachytherapy patients: do we really need general or regional anesthesia?","volume":"31","author":"Schenck M","year":"2013","unstructured":"Schenck M, Schenck C, R\u00fcbben H, Stuschke M, Schneider T, Eisenhardt A, Rossi R. Pudendal nerve block in HDR-brachytherapy patients: do we really need general or regional anesthesia?. World J Urol. 2013, 31:417-21. 10.1007\/s00345-012-0987-x","journal-title":"World J Urol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2020.04.005","article-title":"COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation","volume":"19","author":"Williams VM","year":"2020","unstructured":"Williams VM, Kahn JM, Harkenrider MM, et al.. COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation. Brachytherapy. 2020, 19:401-11. 10.1016\/j.brachy.2020.04.005","journal-title":"Brachytherapy"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.07.342","article-title":"HDR vs. LDR (Pd103 permanent implants) brachytherapy as monotherapy for prostate cancer. timing to onset and predictors of erectile dysfunction","volume":"60","author":"Ghilezan M","year":"2004","unstructured":"Ghilezan M, Vargas C, Gustafson G, et al.. HDR vs. LDR (Pd103 permanent implants) brachytherapy as monotherapy for prostate cancer. timing to onset and predictors of erectile dysfunction. Int J Radiat Oncol. 2004, 60:442. 10.1016\/j.ijrobp.2004.07.342","journal-title":"Int J Radiat Oncol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.06.1204","article-title":"Comparison of toxicities in high dose rate versus low dose rate brachytherapy as monotherapy in patients with low to favorable intermediate risk prostate cancer","volume":"99","author":"Lee D","year":"2017","unstructured":"Lee D, Li T, Hallman MA, et al.. Comparison of toxicities in high dose rate versus low dose rate brachytherapy as monotherapy in patients with low to favorable intermediate risk prostate cancer. Int J Radiat Oncol. 2017, 99:E252. 10.1016\/j.ijrobp.2017.06.1204","journal-title":"Int J Radiat Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.07.013","article-title":"Prostate brachytherapy case volumes by academic and nonacademic practices: implications for future residency training","volume":"96","author":"Orio PF 3rd","year":"2016","unstructured":"Orio PF 3rd, Nguyen PL, Buzurovic I, Cail DW, Chen YW. Prostate brachytherapy case volumes by academic and nonacademic practices: implications for future residency training. Int J Radiat Oncol Biol Phys. 2016, 96:624-8. 10.1016\/j.ijrobp.2016.07.013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2013.06.004","article-title":"Resident-reported brachytherapy experience in ACGME-accredited radiation oncology training programs","volume":"12","author":"Compton JJ","year":"2013","unstructured":"Compton JJ, Gaspar LE, Shrieve DC, Wilson LD, Griem KL, Amdur RJ, Lee WR. Resident-reported brachytherapy experience in ACGME-accredited radiation oncology training programs. Brachytherapy. 2013, 12:622-7. 10.1016\/j.brachy.2013.06.004","journal-title":"Brachytherapy"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.09.037","article-title":"The transcriptional landscape of radiation-treated human prostate cancer: analysis of a prospective tissue cohort","volume":"100","author":"Keam SP","year":"2018","unstructured":"Keam SP, Caramia F, Gamell C, et al.. The transcriptional landscape of radiation-treated human prostate cancer: analysis of a prospective tissue cohort. Int J Radiat Oncol Biol Phys. 2018, 100:188-98. 10.1016\/j.ijrobp.2017.09.037","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/87209-implementation-of-high-dose-rate-ct-based-prostate-brachytherapy-in-an-academic-teaching-hospital-and-residency-training-program","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:40:35Z","timestamp":1707507635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/87209-implementation-of-high-dose-rate-ct-based-prostate-brachytherapy-in-an-academic-teaching-hospital-and-residency-training-program"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.22494","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,22]]}}}